1033-P: Complications at One Year in a Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India (LANDMARC)

Complications (macrovascular and microvascular) during the first year of LANDMARC, a 3-year prospective observational study (CTRI/2017/05/008452) that included patients with T2D on ≥2 antihyperglycemic medications, were evaluated. Out of 6236 patients (mean baseline values - age: 52.1 years, T2D duration: 8.6 years and A1C: 8.05%) enrolled, 5654 patients completed first year follow-up. Though the mean A1C improved by 0.45% (baseline: 8.05%) at the end of the first year, macrovascular and microvascular complications were noted in an additional 45 and 93 number of participants, respectively. Neuropathy was the most reported complication (baseline: 11.8% and 1-year: 13.1%). Overall, complications were more common in participants with BMI ≥23 kg/m2, A1C ≥7% or having CV risks factors (Table). A total of 21 deaths were reported of which 15 deaths were attributed to CV causes (myocardial infarction [n=7], sudden death [n=6], stroke and coronary artery procedure [n=1, each]). The 1-year results show a higher trend of complications among those who are overweight, or with suboptimal glycemic control or having CV risk factors. Neuropathy was the predominant T2D complication. The 1-year trends on complications from the real-world LANDMARC study, offer insights into disease progression and suggest the need for controlling risk factors and treatment adjustments in patients with T2D.View largeDownload slideView largeDownload slide DisclosureN. Rais: None. R. Ghosh: Employee; Self; Sanofi. S. Krishnan: Employee; Self; Sanofi. A. Nair: Employee; Self; Sanofi. S. Mohanasundaram: Employee; Self; Sanofi. S. K. Menon: Employee; Self; Sanofi. V. Salvi: Employee; Self; Sanofi. D. Chodankar: Employee; Self; Sanofi. C. Trivedi: None. S. Wangnoo: None. A. H. Zargar: None. A. K. Das: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Roche Pharma, Sanofi. K. Kumar: Advisory Panel; Self; Sanofi-Aventis. S. Joshi: Advisory Panel; Self; Abbott, AstraZeneca, Biocon, Franco Indian, Glenmark, Lupin, Marico, Roche, Twinhealth, Zydus, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Novo Nordisk, Sanofi, Serdia Pharmaceuticals (India) Pvt. Ltd. A. Mithal: Advisory Panel; Self; Eris Lifesciences Limited, Consultant; Self; Glenmark Pharmaceuticals Limited, Lupin Pharmaceuticals, Inc., USV Private Limited, Speaker’s Bureau; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Novo Nordisk, Sanofi. S. Kalra: Speaker’s Bureau; Self; Eli Lilly and Company, Novo Nordisk, Sanofi. A. Unnikrishnan: Advisory Panel; Self; Sanofi-Aventis, Other Relationship; Self; Novo Nordisk A/S, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes. H. Thacker: None. B. Sethi: None. S. Chowdhury: None.FundingSanofi